Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.47 |
| ▸ | ADA | P00813 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083241 | 1.00 | ADORA2A (0.54) | ADORA2APRMT5WDR77ADORA3ADORA1 | |
| SCHEMBL731577 | 0.83 | ADORA2A (0.53) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL19536253 | 0.83 | ADORA2A (0.53) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL19536251 | 0.83 | ADORA2A (0.53) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL5844191 | 0.83 | ADORA2A (0.58) | ADORA2APRMT5WDR77ADORA3ADORA1 | |
| SCHEMBL4552286 | 0.81 | ADORA2A (0.50) | ADORA2APRMT5WDR77ADORA3ADORA1 | |
| SCHEMBL4001514 | 0.80 | ADORA2A (0.64) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6727038 | 0.79 | PRMT5 (0.46) | ADORA2APRMT5WDR77ADORA3ADORA1 | |
| SCHEMBL6727224 | 0.79 | PRMT5 (0.46) | ADORA2APRMT5WDR77ADORA3ADORA1 | |
| SCHEMBL16311924 | 0.79 | ADORA2A (0.56) | ADORA2APRMT5WDR77ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459582-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-7629320-B2 | Nucleoside derivatives for treating hepatitis C virus infection | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080249060-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-7425547-B2 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1572097-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004028481-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249060-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | HAVCR2, PNP, NTPCR | ADORA2A 174/4885PRMT5 2120/4885WDR77 2755/4885 |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA2A 174/4885PRMT5 2120/4885WDR77 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.